Robeco Institutional Asset Management B.V. Has $1.55 Million Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Robeco Institutional Asset Management B.V. cut its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 97.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,060 shares of the medical device company's stock after selling 1,003,493 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in DexCom were worth $1,546,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of DXCM. Vanguard Group Inc. grew its holdings in shares of DexCom by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company's stock worth $6,186,539,000 after purchasing an additional 136,282 shares during the period. Blair William & Co. IL boosted its holdings in DexCom by 1.4% during the 1st quarter. Blair William & Co. IL now owns 4,532,687 shares of the medical device company's stock valued at $628,684,000 after acquiring an additional 64,683 shares during the period. Legal & General Group Plc boosted its holdings in DexCom by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company's stock valued at $339,352,000 after acquiring an additional 49,076 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in DexCom by 16.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company's stock valued at $276,538,000 after acquiring an additional 353,019 shares during the period. Finally, 1832 Asset Management L.P. boosted its holdings in DexCom by 1.1% during the 1st quarter. 1832 Asset Management L.P. now owns 1,823,400 shares of the medical device company's stock valued at $252,906,000 after acquiring an additional 20,400 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at DexCom

In other news, COO Jacob Steven Leach sold 746 shares of the firm's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company's stock, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares of the company's stock, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.30% of the company's stock.

DexCom Price Performance

NASDAQ DXCM traded up $1.05 on Friday, reaching $69.96. 3,153,680 shares of the stock traded hands, compared to its average volume of 4,825,686. The firm's fifty day simple moving average is $69.66 and its 200 day simple moving average is $93.42. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The company has a market cap of $27.33 billion, a price-to-earnings ratio of 41.89, a P/E/G ratio of 2.10 and a beta of 1.17. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

Analysts Set New Price Targets

A number of equities analysts recently commented on DXCM shares. BTIG Research lowered their target price on DexCom from $156.00 to $120.00 and set a "buy" rating for the company in a report on Friday, July 26th. Morgan Stanley decreased their price objective on DexCom from $120.00 to $75.00 and set an "equal weight" rating for the company in a research note on Friday, July 26th. UBS Group decreased their price objective on DexCom from $163.00 to $95.00 and set a "buy" rating for the company in a research note on Friday, July 26th. Canaccord Genuity Group reiterated a "buy" rating and issued a $145.00 price objective on shares of DexCom in a research note on Tuesday, July 23rd. Finally, Raymond James decreased their price objective on DexCom from $115.00 to $99.00 and set a "strong-buy" rating for the company in a research note on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.